Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.33 |
| ▸ | HPGD | P15428 | 4/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.33 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29240964 | 1.00 | ALDH1A1 (0.33) | ALDH1A1HPGDMAPTTHRBTDP1 | |
| SCHEMBL14752505 | 0.67 | — | — | |
| SCHEMBL1979222 | 0.67 | IGF1R (0.42) | KMT2AMEN1 | |
| SCHEMBL22660732 | 0.65 | KMT2A (0.44) | ALDH1A1MAPTTDP1SMN1; SMN2KMT2A | |
| SCHEMBL1933837 | 0.65 | KMT2A (0.44) | ALDH1A1MAPTTDP1SMN1; SMN2KMT2A | |
| SCHEMBL22660731 | 0.65 | KMT2A (0.44) | ALDH1A1MAPTTDP1SMN1; SMN2KMT2A | |
| SCHEMBL6498646 | 0.64 | CYP3A4 (0.31) | KMT2A | |
| SCHEMBL6050469 | 0.64 | CYP3A4 (0.31) | KMT2A | |
| SCHEMBL29240989 | 0.63 | GSK3B (0.39) | — | |
| SCHEMBL29240988 | 0.63 | GSK3B (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107840845-B | Novel use of amine compound | 上海璃道医药科技有限公司 | 2024-07-02 | — | — | CN | disclosed |